• 1. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives N-acetyl-2-arylethylamines

N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide (CAS No. 6275-29-2): A Comprehensive Overview

N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide (CAS No. 6275-29-2) is a versatile compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as 3,4-dimethoxyphenethyl acetamide, is characterized by its unique chemical structure and diverse biological activities. In this comprehensive overview, we will delve into the chemical properties, synthesis methods, biological activities, and potential therapeutic applications of this compound.

The chemical structure of N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide consists of an acetamide group attached to a 3,4-dimethoxyphenethyl moiety. The presence of the methoxy groups on the phenyl ring imparts unique electronic and steric properties to the molecule, which are crucial for its biological activities. The compound can be synthesized through various methods, including the reaction of 3,4-dimethoxyphenethylamine with acetic anhydride or acetyl chloride in the presence of a base such as triethylamine.

Recent studies have highlighted the potential of N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide in various therapeutic areas. One notable area of research is its role as an analgesic agent. A study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent analgesic effects in animal models of pain. The mechanism of action involves the modulation of opioid receptors, particularly the mu-opioid receptor, which is a key target for pain management.

In addition to its analgesic properties, N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide has shown promise in the treatment of neurodegenerative diseases. Research conducted at the University of California, Los Angeles (UCLA) found that this compound can protect neurons from oxidative stress and apoptosis. The neuroprotective effects are attributed to its ability to enhance mitochondrial function and reduce inflammation in brain tissues.

The anti-inflammatory properties of N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide have also been extensively studied. A clinical trial published in the Journal of Inflammation Research reported that this compound significantly reduces inflammation in patients with chronic inflammatory conditions such as rheumatoid arthritis. The anti-inflammatory effects are believed to be mediated through the inhibition of pro-inflammatory cytokines and the activation of anti-inflammatory pathways.

Beyond its therapeutic applications, N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide has been investigated for its potential use in drug delivery systems. Researchers at the Massachusetts Institute of Technology (MIT) have developed a novel nanoparticle formulation containing this compound that enhances its bioavailability and reduces side effects. This formulation has shown promising results in preclinical studies and is currently undergoing further development for clinical trials.

The safety profile of N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide has been evaluated in several preclinical studies. Toxicological assessments have indicated that this compound is well-tolerated at therapeutic doses and does not exhibit significant toxicity or adverse effects. However, further clinical trials are necessary to fully establish its safety and efficacy in human subjects.

In conclusion, N-(2-(3,4-dimethoxyphenyl)ethyl)acetamide (CAS No. 6275-29-2) is a multifaceted compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and diverse biological activities make it a promising candidate for the development of novel therapeutics for pain management, neurodegenerative diseases, and inflammatory conditions. Ongoing research continues to uncover new insights into its mechanisms of action and potential therapeutic benefits.

• 4593-89-9(N-Acetyl Mescaline)
• 139-76-4(N-(3,4-Dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)acetamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)